BDNF/NT 3 Growth Factors Receptor – Pipeline Review, H2 2019 : ResearchByMarkets.com

Research By Markets adds Market Research Report - BDNF/NT 3 Growth Factors Receptor – Pipeline Review, H2 2019 : ResearchByMarkets.com

For detailed information: https://www.researchbymarkets.com/report/bdnf-nt-3-growth-factors-receptor-pipeline-review-h2-2019-452559.html

BDNF/NT 3 Growth Factors Receptor – Pipeline Review, H2 2019

Summary

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report BDNFNT 3 Growth Factors Receptor – Pipeline Review, H2 2019, outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) – BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2, 8 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Ophthalmology, Cardiovascular, Ear Nose Throat Disorders, Metabolic Disorders and Non Malignant Disorders which include indications Alzheimer’s Disease, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Central Nervous System (CNS) Tumor, Fibrosarcoma, Huntington Disease, Metastatic Colorectal Cancer, Metastatic Melanoma, Multiple Sclerosis, Neuroblastoma, Papillary Thyroid Cancer, Parkinson’s Disease, Salivary Gland Cancer, Squamous Cell Carcinoma, Thyroid Cancer, Traumatic Brain Injury, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Bladder Cancer, Brain Cancer, Carcinoid Tumor, Cervical Cancer, Charcot-Marie-Tooth Disease, Colon Cancer, Depression, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hormone Sensitive Breast Cancer, Ischemic Optic Neuropathy, Keratitis, Kidney Cancer (Renal Cell Cancer), Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Major Depressive Disorder, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Nerve Injury, Neurodegenerative Diseases, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Neurology, Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Paraganglioma (Glomus Jugulare Tumor), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Post-Traumatic Stress Disorder (PTSD), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rett Syndrome, Rhabdomyosarcoma, Sarcomas, Sleep Disorders, Soft Tissue Sarcoma, Stroke, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Ureter Cancer, Urethral Cancer and Wilms’ Tumor (Nephroblastoma).

Furthermore, this report also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
– The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
– The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
Addex Therapeutics Ltd
AlzeCure Pharma AB
AnHeart Therapeutics Inc
Bayer AG
Boehringer Ingelheim International GmbH
Celon Pharma SA
Chronos Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Handok Inc
MimeTech Srl
Neurodegeneration Therapeutics Inc
Otonomy Inc
PharmatrophiX Inc
Takeda Pharmaceutical Co Ltd
Zebra Biologics Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/452559

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.